What changed: r1 to r2
No authored reason recorded.
Retrieval clocks and internal hashes are excluded. Changed source or accounting definitions are not automatically an economic restatement. The authored reason describes the destination revision.
| Field | Before | After |
|---|---|---|
| /business/description | Not yet authored. | We are an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless platform therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device commercially in 2012. In 2024, we commenced commercialization activities for iDose TR , an intracameral procedural pharmaceutical implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. We also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus, that was approved by the United States (U.S.) Food and Drug Administration (FDA) in 2016. Beyond our approved products, we continue to develop and advance a robust pipeline of novel, dropless platform technologies designed to advance the standard of care and improve outcomes. |
| /business/drivers/0 | Not yet authored. | We are an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless platform therapies and commercializing associated. |
| /business/drivers/1 | Not yet authored. | Beyond our approved products, we continue to develop and advance a robust pipeline of novel, dropless platform technologies designed to advance the standard. |
| /business/drivers/2 | Not yet authored. | In June 2025, we received European Union (EU) Medical Device Regulation (MDR) certification for our iStent family of products, including the iStent infinite. |
| /earnings/next_report_date | None | 2026-10-27 |
| /earnings/source | No published note dates the next report. | estimated from 10-Q filed 2026-07-29 plus 90 days |
| /memory/bands/10d/p10 | -9.706 | -23.395 |
| /memory/bands/10d/p50 | 0.78 | -1.736 |
| /memory/bands/10d/p90 | 13.736 | 16.508 |
| /memory/bands/10d/p_up | 0.557 | 0.435 |
| /memory/bands/1d/p10 | -2.506 | -5.43 |
| /memory/bands/1d/p50 | 0.366 | 0.158 |
| /memory/bands/1d/p90 | 3.387 | 7.218 |
| /memory/bands/1d/p_up | 0.577 | 0.507 |
| /memory/bands/5d/p10 | -5.643 | -14.847 |
| /memory/bands/5d/p50 | 0.183 | -0.527 |
| /memory/bands/5d/p90 | 8.305 | 11.776 |
| /memory/bands/5d/p_up | 0.52 | 0.462 |
| /meta/as_of | 2026-09-17 | 2026-09-18 |
| /meta/business_authored | None | False |
| /meta/extract_accession | None | 0001193125-26-061944 |
| /meta/extract_filed | None | 2026-02-23 |
| /meta/extract_form | None | 10-K |
| /meta/extract_source | None | filing |
| /meta/extract_url | None | https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/gkos-20251231.htm |
| /meta/revision | 1 | 2 |
| /thesis/view | Not yet authored. | |
| /thesis/what_changes_it | Not yet authored. |